Valuation: Immuneering Corporation

Market Cap 226M 202M 185M 168M 316M 21.4B 322M 2.21B 892M 11.29B 848M 830M 35.67B P/E 2026 *
-2.78x
P/E 2027 * -2.26x
Enterprise Value 226M 202M 185M 168M 316M 21.4B 322M 2.21B 892M 11.29B 848M 830M 35.67B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
86.08%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Immuneering Corporation

1 day-6.81%
1 week-5.93%
Current month-6.81%
1 month-14.25%
3 months-15.50%
6 months-35.01%
Current year-46.96%
1 week 3.44
Extreme 3.445
4.16
1 month 3.38
Extreme 3.38
4.16
Current year 3.38
Extreme 3.38
8.48
1 year 3.38
Extreme 3.38
8.48
3 years 1
Extreme 1
10.08
5 years 1
Extreme 1
31.88
10 years 1
Extreme 1
33.99
Manager TitleAgeSince
Chief Executive Officer 44 01/02/2008
Director of Finance/CFO 62 16/07/2026
Chief Tech/Sci/R&D Officer - 01/08/2023
Director TitleAgeSince
Chairman 81 01/01/2008
Director/Board Member 44 01/02/2008
Director/Board Member 72 27/04/2021
Date Insider Type Main position Quantity % Market Cap. Importance
16/07/26 Other

Chief Financial Officer

225,000 0.3478%
16/07/26 Free

Chief Financial Officer

650,000 1.0047%
13/03/26 Free

Head of Human Resources

3,628 0.0056%
Change 5-day change 1-year change 3-year change Capi.($)
-6.81%-5.93%-49.20%-41.83% 226M
-2.37%-5.03%+39.49%+62.39% 62.23B
-0.03%+0.03%+10.31%+68.17% 54.92B
-0.31%+1.35%+19.51%+95.81% 55.26B
-3.33%-5.54%+19.39%+35.69% 42.59B
-2.45%-2.59%+16.36%+98.45% 41.08B
-1.64%+2.32%+219.80%+789.69% 40.33B
-0.35%+22.19%+96.41%+81.29% 33.12B
+0.21%+1.05%+14.81%+46.96% 32.61B
-2.90%+17.12%-42.35%+337.07% 23.98B
Average -2.00%+3.25%+34.45%+157.37% 38.63B
Weighted average by Cap. -1.43%+2.74%+44.30%+162.11%

Financials

2026 *2027 *
Net sales - -
Net income -81.67M -72.91M -66.91M -60.86M -114M -7.73B -116M -799M -322M -4.08B -307M -300M -12.89B -113M -101M -92.69M -84.32M -158M -10.71B -161M -1.11B -446M -5.65B -425M -416M -17.86B
Net Debt - -
Projected Income Statement - Annual - Immuneering Corporation
Logo Immuneering Corporation
Immuneering Corporation is a late-stage clinical oncology company, with an initial focus on patients with RAS, RAF and other mitogen-activated protein kinase (MAPK)-driven cancers. The Company's lead product candidate, atebimetinib (IMM-1-104), is an investigational, oral, once-daily Deep Cyclic Inhibitor of MEK. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company's development pipeline also includes its additional clinical-stage product candidate envometinib (IMM-6-415) and other pre-clinical research programs, including research focused on validated core cancer-signaling pathways outside of the MAPK pathway. The Company's Deep Cyclic Inhibition (DCI) platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling. Its Deep Cyclic Inhibitors inhibit clinically-validated core signaling pathways, such as the MAPK pathway.
Employees
65
Date Price Change Volume
02/11/26 $3.490 -6.81% 799,888
30/10/26 $3.745 -6.84% 1,138,863
29/10/26 $4.020 +0.75% 777,032
28/10/26 $3.990 +4.18% 1,442,688
27/10/26 $3.830 +3.23% 700,080
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Immuneering Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
3.490USD
Average target price
17.00USD
Spread / Average Target
+387.11%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Immuneering Corporation
  1. Stock Market
  2. Stocks
  3. IMRX Stock